Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 25/100

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Key Takeaway: Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged failures in disclosing material information during the period of August 3, 2023, to December 26, 2025. This comes in the wake of disappointing results from its Phase 3 studies of setrusumab for osteogenesis imperfecta, which did not meet expected outcomes, leading to a 42% drop in stock price. Investors with losses over $100,000 are urged to file lead plaintiff applications by April 6, 2026. The lawsuit is being heard in the Southern District of New York.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ultragenyx's Phase III studies for setrusumab failed to demonstrate a statistically significant reduction in fracture rates.
  • The company's stock price fell approximately 42% following the announcement of the study results.
  • Ultragenyx is facing a securities class action lawsuit for failing to disclose material information.

Full Press Release Details

NEW ORLEANS, April 02, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

Investors must file lead plaintiff applications by April 6, 2026.

What company is involved in the class action lawsuit?

The class action lawsuit involves Ultragenyx Pharmaceutical Inc.

What triggered the decline in Ultragenyx's share price?

The share price fell after the Phase 3 studies for setrusumab failed.

Who can assist with legal options regarding this case?

Lawyers at Kahn Swick & Foti, LLC can discuss legal options.

Where can investors find more information on the case?

Investors can visit https://claimsfiler.com/cases/nasdaq-rare/ for details.

Last updated: Apr 2, 2026